- Procaps Group is a family-owned Latin American pharmaceutical
company established over 40 years ago that has grown into a leading
integrated pharma company with a presence in 13 countries and
product reach in 50 markets modernizing oral drug delivery
technology and manufacturing capabilities.
- Procaps Group’s state-of-the-art manufacturing capabilities
provide innovative delivery technologies protected by an extensive
IP moat and supported by industry accolades such as the first
FDA-approved pharmaceutical plant in South America for selling Rx
products into the U.S.
- Procaps Group today is the largest pharmaceutical contract
development and manufacturing organization “CDMO” in Latin America
and top 3 globally in terms of volume of softgel production
capacity.
- Procaps Group currently employs 5,000 people across 13
countries with a strong history and focus on ESG principles
including resource-saving policies, HR and social programs and
corporate policies.
- Procaps Group generated gross revenue of $388 million and
Adjusted EBITDA of $90 million in 2020 and is on track to reach
$436 million in gross revenue and $105 million in Adjusted EBITDA
in 2021. Procaps Group expects full-year Adjusted EBITDA margin
expansion from 22% in 2019 to 26% in 2021 with strong positive free
cash flow. Approximately 44% of Procaps Group revenue in 2020 was
USD-denominated.
- Transaction represents the first ever Latin American focused
SPAC to include a fully committed and over-subscribed SPAC-related
ordinary share PIPE.
- Transaction is expected to enable further investment in growth
and new product categories and positions Procaps Group to
capitalize on favorable regional dynamics through organic growth in
B2B & B2C segments.
- Transaction also positions the Company to drive inorganic
growth through a roll-up strategy focused on mid-sized companies in
the region. The Company’s M&A plan will focus on pharma and
CDMO targets, as well as the possibility for transformational
acquisitions in the future.
- Transaction represents attractive entry valuation at 10.75X
estimated 2021 EV/EBITDA multiple versus global CDMO and
pharmaceutical industry comparable companies.
- Combined Company to have an implied initial enterprise value of
approximately $1.1 billion, and expected to have an estimated $300
million in gross cash proceeds after closing, including a $100
million fully committed PIPE.
- Combined Company strategically positions Procaps Group as a
differentiated Latin American integrated pharma company leveraging
a proprietary and proven M&A strategy that has the potential to
deliver significant Adjusted EBITDA growth and margin
expansion.
- The PIPE was raised from a broad group of Latin American
investors, healthcare investors and thought leaders. These include
pan-regional funds such as Compass Group and Moneda Asset
Management, as well as Chilean-based Consorcio Seguros, among
several other unnamed global and healthcare investors.
- Transaction is expected to close in the third quarter of 2021,
with the Combined Company expected to be listed on the Nasdaq
Capital Market under the symbol “PROC.”
- A joint investor conference call to discuss the proposed
transaction will be conducted today, March 31, 2021, at 11:00 AM
Eastern time.
Union Acquisition Corp. II (NASDAQ: LATN) (“LATN”), a special
purpose acquisition company founded by Kyle P. Bransfield, today
announced execution of a definitive business combination agreement
along with a fully committed PIPE financing agreement with Procaps
Group, a leading integrated international healthcare and
pharmaceutical company, its newly created wholly-owned subsidiary,
Procaps Group, S.A. (the “Company”), and the Company’s wholly-owned
Cayman Island subsidiary (the “Merger Sub”). Following a series of
transactions pursuant to the business combination agreement,
Procaps Group and LATN will ultimately become wholly-owned
subsidiaries of the Company (the “Combined Company”).
The Combined Company will be led by Ruben Minski, Founder,
Chairman of the Board and Chief Executive Officer of Procaps Group.
The Company’s ordinary shares (the “Procaps Ordinary Shares”) are
expected to be listed on the Nasdaq Capital Market under the ticker
symbol “PROC.”
A group of leading investors has committed to participate in a
PIPE to acquire $100 million of ordinary shares of LATN at $10.00
per share that will close simultaneously with the business
combination. The Combined Company will also receive up to $200
million held in LATN’s trust account at closing of the transaction,
subject to any redemptions by existing LATN shareholders.
Additionally, all Procaps Group shareholders’ Procaps Ordinary
Shares will be subject to a 6-month lock-up, subject to certain
exceptions discussed in further detail below.
Alejandro Weinstein is a London-based serial healthcare
entrepreneur who will serve as chairman of a newly-formed M&A
committee, and take a leadership position in guiding the Combined
Company’s M&A roll-up strategy.
Procaps Group Highlights
1. Founded in 1977, Procaps is a leading integrated
international healthcare and pharmaceutical company with a
successful history of growth and diversification.
- Largest pharmaceutical integral CDMO (“iCDMO”) in Latin America
and top 3 preferred supplier globally in terms of volume of softgel
production capacity.
- Proprietary portfolio of branded Rx and OTC products and
services sold, distributed or provided to over 50 markets with a
focus on differentiated, strong margin and high barrier to entry
products.
- Extensive scientific expertise and robust pipeline with more
than 500 formulations, developing more than 50 products per year
with in-house R&D.
- Vertically and horizontally integrated to provide oral drug
delivery technology and manufacturing capabilities at premium
prices at competitive costs.
- 6 state-of-the-art manufacturing facilities in Latin America
including first FDA-approved pharmaceutical plant in South America
for selling Rx products into the U.S.
- Employs over 5,000 people across 13 countries with highly
accomplished management team.
- Over 30 patents granted (over 50 pending) and over 5,000
trademarks.
2. Business Units/Product Lines
- Softigel - iCDMO services specializing in Soft Gelatin Capsules
(SGC) and derivative technologies.
- Farma - Formulates, manufactures and markets branded
prescription drugs.
- Clinical Specialties - Develops, manufactures and markets
high-complexity drugs for hospital use.
- VitalCare - Develops, manufactures and markets OTC consumer
healthcare products.
- Diabetrics - Provides integrated diabetes solutions.
3. A leading regional player with strong diversification by
product and geography positioned to drive regional
consolidation.
- Approximately 44% of Procaps revenue in 2020 was
USD-denominated.
- A leading player in both Colombia and Central America, which
combined represents one of the largest pharma markets in Latin
America.
- Well positioned in key markets with attractive growth prospects
due to favorable regional dynamics.
4. Focus on organic and inorganic growth with increased margin
expansion through agile business model that identifies and
maximizes growth and time-to-market.
- Over 600 new product launches estimated in the next 3
years.
- Working capital investment improves liquidity position to
obtain important cost efficiencies.
- Growth from existing portfolio and entrance into new
therapeutic areas – products with significant growth potential
accelerate the current e-Health platform.
- Internationalization of existing portfolio - on-going efforts
to expand footprint of successful products outside of
Colombia.
- Development of new, innovative pharma solutions - reliable and
recognized track record on the development of new oral delivery
technologies.
- Organic growth through capital deployed to capex improvement
including:
- Capacity expansion of new lyophilization production lines
- Plant and operational improvements
- Improve automatization processes
- Inorganic growth through established M&A platform with a
43-year proven track record.
- Procaps Group positioned to capitalize on favorable regional
dynamics through M&A
- Emerging pharma markets are fragmented – 2nd & 3rd
generation families
- Synergies through innovation and economies of scale
- Sector expertise and technical knowledge
- Lower cost of capital and access to capital markets
- Alejandro Weinstein appointed Chairman of M&A Committee to
lead roll-up strategy of mid-sized companies in Latin America.
- Pharma targets in Mexico, Central America and the Andean
Region
- CDMO targets in Mexico and Brazil
- Key development areas including telehealth and digital health;
ophthalmic products and therapeutic areas; and novel and orphan
drug portfolios.
“For more than 40 years, Procaps has developed integral
pharmaceutical solutions for people’s health, which has led it to
become an important player within the Latin American pharmaceutical
market,” said Ruben Minski, Procaps Founder, Chairman and Chief
Executive Officer. “We are very pleased to have support from
top-tier investors, and access to the U.S. capital markets
following the closing of this proposed transaction, which we
believe will leave Procaps well-capitalized to provide our
innovative pharmaceutical solutions to our global customers and
drive our growth initiatives. Moreover, a key milestone was
achieved in the transaction as it represents the first LatAm SPAC
to have an over-subscribed PIPE in place from very sophisticated
South American healthcare investors and U.S. based funds. This
demonstrates the immense value they see in Procaps Group when you
consider our discounted EV to EBITDA multiple versus industry
comparables in the global CDMO sector and the combination of our
strategic M&A strategy led by Alejandro Weinstein, a proven
pharmaceutical rollup expert.
“With our strong history and focus on Environmental, Social and
Governance principles, we are confident we can provide shareholders
with a multi-pronged investment alternative that supports today’s
healthcare needs and accomplishes this utilizing a sustainable
footprint that we believe will deliver long-term value to your
investment in Procaps. We look forward to opening a new chapter on
our story that leverages:
- Our global reach;
- In-house R&D capabilities driving attractive growth
opportunities;
- Leading integrated pharmaceutical CDMO specialized in
softgels;
- Our proprietary portfolio of branded Rx and OTC products;
- Strategic positioning to capitalize on favorable regional
dynamics; and
- A 43-year proven track record of growth and diversification
with a strong top-line and free cash flow financial profile,”
concluded Minski.
Kyle P. Bransfield, CEO of Union Acquisition Corp. ll added,
“Procaps has built a strong foundation for growth by its tested
business strategy. Our business combination will fuel this
expansion, with a significant focus on a strategic roll-up strategy
that we believe will drive an accelerated competitive position and
value creation. Regional emerging pharma markets are fragmented,
and greenfield pharma projects in big emerging markets are slow and
expensive. Accretive acquisitions in key development areas will
create synergies through innovation and economies of scale and
lower the cost of capital through diversification both
geographically and by business units,” concluded Bransfield.
Procaps Group has assembled a seasoned team of over 5,000
employees, consisting of scientists, clinical, manufacturing,
regulatory and commercial experts. Following the closing of the
transaction, Mr. Minski and Mr. Bransfield will be joined by
certain board members of Procaps Group to form the Combined
Company’s board of directors.
Key Transaction Terms
- Pursuant to the terms of the business combination agreement:
(i) LATN will merge with the Merger Sub and LATN’s ordinary shares
and warrants to purchase ordinary shares of LATN will be exchanged
for Procaps Ordinary Shares and warrants to purchase Procaps
Ordinary Shares, respectively; and (ii) the current shareholders of
Crynssen Pharma Group Limited (“Procaps Group”) will contribute all
of their shares of Procaps Group to the Company in exchange for
Procaps Ordinary Shares and, in the case of the International
Finance Corporation (“IFC”), one of Procaps Group’s shareholders,
Procaps Ordinary Shares and redeemable B shares of the Company,
resulting in Procaps Group becoming a wholly-owned subsidiary of
the Company following the consummation of such exchanges (i.e., the
Combined Company).
- Under the terms of the proposed transaction, Procaps Group’s
shareholders will receive an aggregate of 97.1 million Procaps
Ordinary Shares and, in addition to Procaps Ordinary Shares, IFC
will receive 6 million redeemable B shares of the Company, in
exchange for their existing Procaps Group ordinary shares, as
contemplated by the terms of the business combination
agreement.
- All Procaps Group shareholders’ Procaps Ordinary Shares will be
subject to a 6-month lock-up, with the exception of 4 million
Procaps Ordinary Shares held by certain Procaps Group shareholders,
which will be subject to a shorter lock-up expiring on the earlier
to occur of the date that is 90 days from the date of the
consummation of the business combination and the date which the
last sale price of the Procaps Ordinary Shares equals or exceeds
$12.00 per share for any 20 trading days within any 30-day trading
period.
- Of the Procaps Ordinary Shares issued to the Procaps Group
shareholder in the exchange described above, 10,464,612 Procaps
Ordinary Shares will be placed into an escrow account at closing of
the transaction (the “Procaps Escrowed Shares”). 50% of the Procaps
Escrowed Shares will be released to Procaps Group’s shareholders if
the last sale price of the Procaps Ordinary Shares equals or
exceeds $12.50 per share for any 20 trading days within any 30-day
trading period and the remaining 50% will be released to Procaps
Group’s shareholders if the last sale price of the Procaps Ordinary
Shares equals or exceeds $13.00 per share for any 20 trading days
within any 30-day trading period.
- As part of the transaction, LATN’s founders have agreed to
forfeit 2,875,000 of their private warrants. LATN’s founders have
also agreed to place 2,875,000 of the private warrants of the
Combined Company they will receive in the business combination and
1,250,000 Procaps Ordinary Shares into an escrow account (together
with the Procaps Ordinary Shares issuable upon exercise of the
escrowed private warrants, the “LATN Escrowed Shares”). 50% of the
escrowed warrants and 50% of LATN Escrowed Shares will be released
to LATN’s founder if the last sale price of the Procaps Ordinary
Shares equals or exceeds $12.50 per share for any 20 trading days
within any 30-day trading period, and the remaining 50% of the
escrowed warrants and LATN Escrowed Shares will be released to the
LATN founders if the last sale price of the Procaps Ordinary Shares
equals or exceeds $13.00 per share for any 20 trading days within
any 30-day trading period. For the avoidance of doubt, any Procaps
Ordinary Shares released from escrow will remain subject to any
applicable lock-up. The owners of the Procaps Escrowed Shares and
the LATN Escrowed Shares (together, the “Escrowed Shares”) will
retain their economic interests (such as rights to cash dividends,
if any) in, and be able to vote, such Escrowed Shares while they
remain in escrow.
- The Combined Company is expected to receive gross proceeds of
approximately $300 million at the closing of the transaction
assuming no redemptions by LATN’s shareholders. Net proceeds to the
Combined Company are expected to be approximately $215 million
after transaction-related expenses and the redemption of the 6
million redeemable B shares of the Company held by IFC for a total
cash payment of $60 million. Use of net proceeds would be to fund
organic growth and consummate accretive acquisitions.
- In addition to the $200 million held in LATN’s trust account
(assuming no redemptions by LATN’s shareholders), an additional
group of top-tier healthcare investors has committed to participate
in the transaction through an ordinary share PIPE of $100 million
at $10 per share. As noted, this transaction represents the first
ever Latin American focused SPAC to include a fully committed and
over-subscribed SPAC-related ordinary share PIPE.
- Assuming no redemptions by LATN’s shareholders, excluding the
Escrowed Shares and following the redemption of certain Procaps
shares held by the IFC, it is estimated that the current
shareholders of Procaps will own approximately 71% of the issued
and outstanding shares in the Combined Company at closing.
- Transaction value will be 10.75x EV/2021E Adjusted EBITDA,
implying an estimated pro forma enterprise valuation of US$ 1.1
billion based on an estimated Adjusted EBITDA for 2021 of $105
million and excluding the Escrowed Shares.
- Post-transaction pro forma Net Debt/Adjusted EBITDA reduced
from 2X 2020 to minimal net debt 2021, assuming no redemptions and
excluding the Escrowed Shares.
- As part of the transaction, the Procaps Group’s current
management and existing equity holders will roll nearly 100% of
their equity into the Combined Company. All shareholders from the
families will not have any secondary redemptions from the gross
proceeds received. The transaction is expected to close in the
third quarter of 2021.
The transaction has been approved by each of LATN’s and Procaps
Group’s Board of Directors. The transaction is subject to the
approval of LATN and Procaps shareholders and other customary
conditions and is expected to close in the third quarter of
2021.
Additional information about the transaction will be provided in
a Current Report on Form 8-K that will contain an investor
presentation to be filed by LATN with the Securities and Exchange
Commission (“SEC”) and will be available at www.sec.gov. In
addition, LATN intends to file a registration statement on Form F-4
with the SEC, which will also include a proxy statement/prospectus,
and will file other documents regarding the proposed transaction
with the SEC.
Advisors
BTG Pactual acted as sole placement agent on the PIPE and
financial advisor to LATN. Cantor Fitzgerald acted as capital
markets advisor to LATN. Greenhill & Co., LLC acted as
financial and capital markets advisor to Procaps Group. Linklaters
LLP acted as legal counsel to LATN and Greenberg Traurig, LLP acted
as legal counsel to Procaps Group in the transaction.
Conference Call Details
Procaps Group Chief Executive Officer Ruben Minski, Procaps
Group Board Member & Chairman of M&A Committee Alejandro
Weinstein and Union Acquisition Corp. ll Chief Operating Officer
Daniel Fink will host the conference call. The conference call will
be accompanied by a presentation, which can be viewed during the
webcast or accessed via the investor relations section of Procaps’
website here.
To access the call, please use the following information:
Date:
Wednesday, March 31, 2021
Time:
11:00 a.m. EDT, 8:00 a.m. PDT
Toll Free dial-in number:
1-877-407-9716
Toll/International dial-in number:
1-201-493-6779
Conference ID:
13718102
Please call the conference telephone number 5-10 minutes prior
to the start time. An operator will register your name and
organization. If you have difficulty connecting with the conference
call, please contact MZ Group at +1 (949) 491-8235.
The conference call will be broadcast live and available for
replay at http://public.viavid.com/index.php?id=144110 and via the
investor relations section of Procaps’ website here.
A replay of the call will be available for one year following
the conference.
Toll Free Replay Number:
1-844-512-2921
International Replay Number:
1-412-317-6671
Replay ID:
13718102
About Procaps Group
Procaps Group is a developer of pharmaceutical and nutraceutical
solutions, medicines, and hospital supplies that reach more than 50
countries in all five continents. Procaps has a direct presence in
13 countries in Latin America and has more than 5,000 collaborators
working under a sustainable model. Procaps develops, manufactures,
and markets over-the-counter (OTC) and prescription drugs,
nutritional supplements and high-potency clinical solutions. For
more information, visit www.procapsgroup.com or the Company’s
investor relations website investor.procapsgroup.com.
About Union Acquisition Corp. II.
Union Acquisition Corp. II, led by Kyle Bransfield, is a Cayman
Islands exempted company incorporated as a blank check company for
the purpose of entering into a merger, share exchange, asset
acquisition, share purchase, recapitalization, reorganization or
other similar business combination with one or more businesses or
entities. For more information, please click here.
Important Information About the Merger and Where to Find
It
In connection with the proposed transaction, the Company, a
subsidiary of Procaps Group that will be become the holding company
of LATN and Procaps Group as of the closing of the proposed
transaction, is expected to file a registration statement on Form
F-4 (the “Form F-4”) with the U.S. Securities and Exchange
Commission (the “SEC”) that will include a proxy statement of LATN
that will also constitute a prospectus of the Company. LATN,
Procaps Group and the Company urge investors, stockholders and
other interested persons to read, when available, the Form F-4,
including the preliminary proxy statement/prospectus and amendments
thereto and the definitive proxy statement/prospectus and documents
incorporated by reference therein, as well as other documents filed
with the SEC in connection with the proposed transaction, as these
materials will contain important information about Procaps Group,
the Company, LATN and the proposed transaction. After the
registration statement is declared effective, the definitive proxy
statement/prospectus to be included in the registration statement
will be mailed to shareholders of LATN as of a record date to be
established for voting on the proposed business combination. Once
available, shareholders will also be able to obtain a copy of the
Form F-4, including the proxy statement/prospectus, and other
documents filed with the SEC without charge, by directing a request
to: BTG Pactual US Capital, LLC, Attention: Prospectus Department,
Email: OL-BTGPactual-ProspectusDepartment@btgpactual.com. The
preliminary and definitive proxy statement/prospectus to be
included in the registration statement, once available, can also be
obtained, without charge, at the SEC’s website (www.sec.gov).
Participants in the Solicitation
LATN and Procaps Group and their respective directors and
executive officers may be considered participants in the
solicitation of proxies with respect to the proposed business
combination described in this press release under the rules of the
SEC. Information about the directors and executive officers of LATN
is set forth in LATN’s final prospectus filed with the SEC pursuant
to Rule 424(b) of the Securities Act of 1933, as amended (the
“Securities Act”) on October 17, 2019, and is available free of
charge at the SEC’s website at www.sec.gov or by directing a
request to: Union Acquisition Corp. II, 1425 Brickell Ave., #57B,
Miami, FL 33131. Information regarding the persons who may, under
the rules of the SEC, be deemed participants in the solicitation of
the LATN shareholders in connection with the proposed business
combination will be set forth in the registration statement
containing the proxy statement/prospectus for the proposed business
combination when it is filed with the SEC. These documents can be
obtained free of charge from the sources indicated above.
Forward-Looking Statements
This press release contains “forward-looking statements.”
Forward looking statements may be identified by the use of words
such as “forecast,” “intend,” “seek,” “target,” “anticipate,”
“believe,” “expect,” “estimate,” “plan,” “outlook,” and “project”
and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
Such forward-looking statements include projected financial
information, including Adjusted EBITDA margin and free cash flow;
the expected gross cash proceeds from the transaction; expected
future capitalization; the expected listing of the Ordinary Shares
and the closing of the transaction; expectations relating to
Procaps Group’s ability to invest in growth and new product
categories and capitalize on favorable regional dynamics through
organic and inorganic growth; estimated product launches in next
three years; belief that Procaps Group will be sufficiently
capitalized to provide innovative solutions and drive growth
initiatives; and expected synergies through innovation, economies
of scale and lower cost of capital. Such forward-looking statements
with respect to revenues, earnings, performance, strategies,
synergies, prospects, and other aspects of the businesses of LATN,
Procaps Group, or the Combined Company after completion of any
proposed business combination are based on current expectations
that are subject to risks and uncertainties. A number of factors
could cause actual results or outcomes to differ materially from
those indicated by such forward-looking statements. These
statements involve risks, uncertainties and other factors that may
cause actual results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Although
we believe that we have a reasonable basis for each forward-looking
statement contained in this press release, we caution you that
these statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to: (1) the inability to
complete the transactions contemplated by the proposed business
combination; (2) the inability to recognize the anticipated
benefits of the proposed business combination, which may be
affected by, among other things, competition, and the ability of
the combined business to grow and manage growth profitably; (3) the
inability to successfully retain or recruits officers, key
employees, or directors following the proposed business
combination; (4) effects on Union’s public securities’ liquidity
and trading; (5) the market’s reaction to the proposed business
combination; (6) the lack of a market for LATN’s securities; (7)
LATN’s and Procaps Group’s financial performance following the
proposed business combination; (8) costs related to the proposed
business combination; (9) changes in applicable laws or
regulations; (10) the possibility that LATN or Procaps Group may be
adversely affected by other economic, business, and/or competitive
factors; and (11) other risks and uncertainties indicated from time
to time in documents filed or to be filed with the SEC by LATN. We
cannot assure you that the forward-looking statements in this press
release will prove to be accurate. These forward-looking statements
are subject to a number of significant risks and uncertainties that
could cause actual results to differ materially from expected
results, including, among others, the ability to complete the
business combination due to the failure to obtain approval from
LATN shareholders or satisfy other closing conditions in the
Business Combination Agreement, the occurrence of any event that
could give rise to the termination of the Business Combination
Agreement, the ability to recognize the anticipated benefits of the
business combination, the outcome of any legal proceedings that may
be instituted against LATN or Procaps Group following announcement
of the proposed business combination and related transactions, the
impact of COVID-19 on Procaps Group’s business and/or the ability
of the parties to complete the business combination, the ability to
obtain or maintain the listing LATN’s ordinary shares on Nasdaq
following the proposed business combination, costs related to the
proposed business combination, changes in applicable laws or
regulations, the possibility that LATN or Procaps Group may be
adversely affected by other economic, business, and/or competitive
factors, and other risks and uncertainties, including those to be
included under the header “Risk Factors” in the Form F-4 to be
filed with the SEC and those included under the header “Risk
Factors” in the final prospectus of LATN related to its initial
public offering, as well as LATN’s other filings with the SEC.
Should one or more of these risks or uncertainties materialize, or
should any of our assumptions prove incorrect, actual results may
vary in material respects from those projected in these
forward-looking statements. We undertake no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws. Accordingly, you should not put
undue reliance on these statements.
Non-Solicitation
This press release is not a proxy statement or solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed business combination and shall not
constitute an offer to sell or a solicitation of an offer to buy
any securities nor shall there be any sale of securities in any
state or jurisdiction in which such offer, solicitation, or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. No offer of
securities shall be made except by means of a prospectus meeting
the requirements of the Securities Act.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210331005170/en/
Procaps Group Investor Contact: Chris Tyson/Doug Hobbs
SPAC Alpha IR+ (949) 491-8235 LATN@mzgroup.us
LATN Contact: Kyle P. Bransfield Chief Executive Officer
Union Acquisition Corp. II (305) 306-2522
Union Acquisition Corpor... (NASDAQ:LATN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Union Acquisition Corpor... (NASDAQ:LATN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024